Clinical trial NCT04896112: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Official title: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Polycythemia Vera
Keywords: Malignant Myeloid Hematologic Neoplasms
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myeloid malignancies
Myelofibrosis
Polycythemia Vera
Acute Myeloid Leukemia
Lead sponsor: Lynk Pharmaceuticals Co., Ltd
Sponsor class: INDUSTRY
First posted: 2021-05-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002
Primary purpose: TREATMENT

Brief summary: This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), polycythemia vera (PV), or with acute myeloid leukemia (AML).

Detailed description: This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms. The study consists of two periods: the dose escalation, main period and a dose expansion period. In the dose escalation period, successive cohorts of patients with Malignant Myeloid Hematologic Neoplasms will be enrolled to establish the maximum tolerated dose. In the dose expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and patients with primary MF ,PV or PV/ET-MF.

The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms will be evaluated.

Eligibility criteria: Inclusion Criteria:

1. Age: 18 years old or older, male or female.
2. Patients must have histologically or cytologically confirmed tumors of the following types.

   * Dose Escalation Phase: Patients with PMF,PV/ET-MF,PV

     1. Intermediate or high-risk primary myelofibrosis, intermediate or high-risk post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis , or high-risk polycythemia vera who have no available therapy or relapsed after allogeneic hematopoietic cell transplantation.
     2. Symptomatic splenomegaly
     3. Not undergone splenectomy or splenic radiation therapy within 6 months prior to screening.
   * Dose expansion phase: Patients with PMF, PV/ET-MF,PV who relapsed or are intolerant to standard treatment, and relapsed/refractory AML
3. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration
4. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug administration
5. Women of childbearing potential negative pregnancy test at screening. Female patients of childbearing potential, or male patients and their partners should agree to effective contraception from signing ICF until 6 months after the last dose of study drug.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria will be excluded from the clinical study:

1. Allergic to any component of LNK01002.
2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN) reference range, except patients diagnosed as Gilbert's disease
3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by leukemia, which are excluded if higher than 5 times the ULN
4. Glomerular filtration rate or estimated creatinine clearance \< 50 mL/min according to the Cockcroft-Gault formula;
5. Serum amylase or lipase levels higher than the ULN and considered clinically significant
6. International normalized ratio (INR) or partial activated prothrombin time (aPTT) above 1.5 times the ULN reference range
7. Known history of clinically significant liver disease, including viral or other hepatitis:

   a) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative polymerase chain reaction (PCR)
8. Known human immunodeficiency virus (HIV) infection;
9. Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery within 6 months before enrollment, congestive heart failure with New York Heart Association (NYHA) classification of III or above, left ventricular ejection fraction (LVEF) \< 50%, or uncontrolled hypertension, cardiac arrhythmia;
10. Patients with history or presence of clinically relevant non-malignant CNS disease requiring treatment;
11. Patients who have received systemic antineoplastic therapy or radiotherapy within 2 weeks prior to start of study treatment;
12. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60 days prior to the start of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or have graft-versus-host disease (GVHD) requiring ongoing treatment;
13. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start of study treatment;
14. Received CYP3A strong inhibitors or strong inducers less than one week or 5 half-lives (whichever is longer) prior to the start of study treatment;
15. Uncontrolled, active infections requiring intravenous antibiotic treatment;

Primary outcomes:
measure: Assessing the safety and tolerability of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms
timeFrame: 31 days
measure: Assessing maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms
timeFrame: 31 days
measure: Assessing the preliminary antitumor activity of LNK01002
timeFrame: 24 Weeks
Secondary outcomes:
measure: Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV,PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV,PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV, PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV, PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV, PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV,PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
measure: Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV,PV-MF or ET-MF patients
timeFrame: Day 1, Day 2, and Day 15
Other outcomes:
Locations:
city: Farmington Hills
country: United States
facility: Revive Research Institute
state: Michigan
city: Sterling Heights
country: United States
facility: Revive Research Institute
state: Michigan
Study officials:
affiliation: Lynk Pharmaceuticals Co., Ltd
name: Linda Wei, M.D.
role: STUDY_DIRECTOR
References: